# Do GLP-1 Drugs Reduce Cancer Risk? What Studies Show | Buy This GLP

Compare a records study on individual cancers with randomized trial evidence on overall cancer risk for people taking GLP-1 medicines.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/do-glp1-drugs-reduce-cancer-risk
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# Do GLP-1 Drugs Reduce Cancer Risk? What Studies Show

A records study found lower incidence of some cancers in a dose subgroup. Pooled randomized trials found no clear difference in overall cancer risk.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Therapeutic dose vs bariatric surgery · no difference · colorectal · 0.72 · pancreatic · 0.63 · Liver cancer: no statistically clear difference · At any dose rather than therapeutic: nothing significant. · No confidence intervals are published in the summary.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   One records study found fewer diagnoses of some cancers in a therapeutic-dose subgroup.
-   A pooled analysis of 148 randomized trials found no clear difference in overall cancer risk.
-   The findings do not establish a role for GLP-1 medicines in cancer prevention.

## What the health-record study found

Bitar and colleagues identified 662,013 adults using semaglutide or tirzepatide, 272,343 who underwent bariatric surgery, and 158,446 who used other weight-loss medicines. The study used electronic health records for adults with obesity who did not have diabetes. Researchers matched participants for their comparisons[\[1\]](https://buythisglp.com/research/do-glp1-drugs-reduce-cancer-risk#ref-1).

At therapeutic doses, the recorded incidence of colorectal and pancreatic cancer was lower than in the surgery group (hazard ratios 0.72 and 0.63, respectively). Compared with other weight-loss medicines, colorectal cancer incidence was lower (hazard ratio 0.68), while pancreatic cancer showed no statistically clear difference. Neither comparison showed a clear difference in liver cancer. The analysis that included people at any dose found no statistically clear differences [\[1\]](https://buythisglp.com/research/do-glp1-drugs-reduce-cancer-risk#ref-1).

The [survey of doses people take in practice](https://buythisglp.com/research/what-dose-do-most-people-actually-reach) puts the dose distinction in context. People who reach higher doses may differ from those who remain on lower doses. The cancer study compared records within dose groups, so it cannot establish that escalating the dose changes cancer risk.

## What randomized trials add

A pooled analysis of 148 randomized trials with 168,875 participants found no statistically clear difference in overall cancer risk (risk ratio 0.99, 95% confidence interval 0.92 to 1.05). An exploratory prostate cancer signal did not survive correction for multiple testing [\[3\]](https://buythisglp.com/research/do-glp1-drugs-reduce-cancer-risk#ref-3). These pooled results describe the outcomes captured during trial follow-up. Our review of [GLP-1 use after a cancer diagnosis](https://buythisglp.com/research/can-you-take-a-glp1-after-cancer) covers a different question about care during and after treatment. The pooled trials address cancer incidence.

For people considering a GLP-1 after a cancer diagnosis, a review of the clinical evidence highlights separate concerns such as unintended weight loss and loss of muscle during treatment [\[2\]](https://buythisglp.com/research/do-glp1-drugs-reduce-cancer-risk#ref-2). Discuss the treatment goal and nutritional risks with the clinicians who manage your cancer care.

## Frequently asked

Do GLP-1 drugs prevent cancer?

The evidence does not establish that. Some cancers were less common in a subgroup of one records study. A pooled analysis of randomized trials found no clear difference in overall cancer risk.

Does a higher GLP-1 dose lower cancer risk?

The records study cannot establish a dose effect. The groups may differ in ways related to cancer risk, including why people reached or stayed at a particular dose.

## Sources

1.  \[1\] Bitar ER, Besir K, Cummins KC, Sears O, El Moheb M, McKee K (2026). Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs Journal of Gastrointestinal Surgery. [PMID 42447648](https://pubmed.ncbi.nlm.nih.gov/42447648/)
2.  \[2\] Agurs-Collins T, Sauter ER (2026). GLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review Cancers. [PMID 42650025](https://pubmed.ncbi.nlm.nih.gov/42650025/)
3.  \[3\] Liang W, Huang Z, Long Y, et al. (2026). Glucagon-like peptide-1 receptor agonists and risk of cancer: a systematic review and meta-analysis of randomized controlled trials Scientific Reports. [Source](https://www.nature.com/articles/s41598-026-63543-7)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
